BioCentury | Feb 22, 2017
Distillery Therapeutics

Infectious disease

INDICATION: Leishmaniasis Cell line and mouse studies identified a pyrazolopyridine-based compound that could help treat leishmaniasis. Chemical synthesis and testing in a Leishmania donovani -infected mouse macrophage cell line of pyrazolopyridine analogs yielded a compound...
BioCentury | Jan 4, 2017
Emerging Company Profile

Orum’s forum

...showed that both antibodies were delivered into the cytosol. The team used the system on KARS...
...been identified as an autoantibody target in autoimmune diseases. A V L -modified antibody against KARS...
...France Sorrento Therapeutics Inc. (NASDAQ:SRNE), San Diego, Calif. Targets KRAS - K-Ras KARS (KRS) - Lysyl-tRNA synthetase...
BioCentury | Mar 11, 2013
Product Development

Neomics' new tricks

...pathways as targets for companion diagnostics. These include a diagnostic for lysyl-tRNA synthetase ( KARS ; KRS...
...companies developing therapeutics targeting the ARS pathway. Yuhan Corp. is developing a drug using the KRS...
BioCentury | Jul 19, 2012
Distillery Therapeutics

Indication: Infectious disease

...therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Infectious disease Malaria Plasmodium falciparum lysyl-tRNA synthetase...
BioCentury | May 24, 2012
Targets & Mechanisms

Getting selective for gamma

Cellzome AG and Exelixis Inc. have independently designed the first highly selective inhibitors of the g-isoform of phosphoinositide 3-kinase . 1,2 Exelixis plans to out-license its inhibitors, whereas last week's acquisition of Cellzome by GlaxoSmithKline plc...
BioCentury | Feb 27, 2012
Product Development

Take your PI(3)K

Questions remain about the optimal selectivity profiles for PI3K inhibitors, but big biopharmas are already making their bets. The shift from interesting science to investable compounds - about two decades in the making - hinged on marrying...
BioCentury | Oct 13, 2011
Targets & Mechanisms

Getting fat off PI3Kgamma

A team of Swiss researchers has shown that knocking out an isoform of the cancer target phosphoinositide 3-kinase led to weight loss and increased insulin sensitivity in mice. 1 The challenge will be designing compounds...
BioCentury | Aug 4, 2011
Distillery Therapeutics

Indication: Neurology

Indication Target/marker/ pathway Summary Licensing status Publication and contact information Neurology Neuropathy Histone deacetylase 6 (HDAC6); heat shock 27 kDa protein 1 (Hspb1; Hsp27); tubulin Mouse studies suggest HDAC6 inhibitors could help treat Charcot-Marie-Tooth (CMT)...
BioCentury | May 26, 2011
Targets & Mechanisms

Giving Treg cells a boost

Toxicity due to widespread epigenetic effects has prevented the use of pan- HDAC inhibitors in indications beyond advanced cancer, in which at least one such drug has reached the market. A team at the Perelman...
BioCentury | May 12, 2011
Distillery Therapeutics

Indication: Inflammation

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Inflammation Inflammatory disease Phosphoinositide 3-kinase-b (PI3Kb); PI3Kd Mouse studies suggest that inhibiting both PI3Kb and PI3Kd could help treat inflammatory diseases. In...
Items per page:
1 - 10 of 10